Pacira BioSciences, Inc. Announces Pricing of $350.0 Million Aggregate Principal Amount of 0.750% Convertible Senior Notes due 2025GlobeNewsWire • 07/07/20
Pacira BioSciences, Inc. Announces Proposed Offering of $300.0 Million Aggregate Principal Amount of Convertible Senior NotesGlobeNewsWire • 07/06/20
Pacira BioSciences Reports Preliminary Total Revenue of $75.5 Million for Second Quarter of 2020GlobeNewsWire • 07/06/20
Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy SynthesGlobeNewsWire • 07/02/20
Flexion Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare ConferenceGlobeNewsWire • 06/16/20
Pacira BioSciences to Present at the 2020 BMO Prescriptions for Success Healthcare ConferenceGlobeNewsWire • 06/16/20
How Flexion Therapeutics (FLXN) Stock Stands Out in a Strong IndustryZacks Investment Research • 05/14/20
Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/11/20
Flexion Therapeutics' (FLXN) CEO Michael Clayman on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/08/20
Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research Society International OARSI 2020GlobeNewsWire • 05/01/20